Alexandria Real Estate Equities has lost nearly 10% in a week, dropping to $48.87 after its Q2 print landed with a thud — and the Street's response is still playing out in real time.
The earnings reaction is the defining event. The stock fell 5% the day after the August 3 report, erasing the recovery that had built since the founder's spring buying cluster. That move is a sharp reversal from the prior quarter, when ARE gained 0.8% the day after results and nearly 2.5% across the following week. The one-month decline now stands at 7%, and the stock has given back everything it gained in July. What changed is the delivery: the Q2 print appears to have confirmed the bear thesis around rising tenant move-outs, lower occupancy, and a significant step-down in core earnings — the same headwinds analysts flagged in the bear case months ago.
The options market is flashing an unusual signal, and it cuts against the obvious read. Despite the selloff, the put/call ratio has collapsed to 0.85 — nearly 2.6 standard deviations below its 20-day average of 1.07, making it the most call-skewed reading of the past year. That's a striking divergence from a stock down almost 10% on the week. It suggests a cohort of investors moved into calls either as a bounce trade or as a hedge against short positions — not the defensive piling-in you'd normally expect after a sharp post-earnings drop. Short interest, meanwhile, has edged up roughly 3% over the week to 4.5% of the free float, a modest but directionally consistent build. Borrowing remains essentially free at under 0.5%, and availability is extremely loose at over 2,500% — meaning there is no constraint whatsoever on adding short exposure. The borrow market is not the story here.
The analyst community's post-earnings response is split. BNP Paribas kept its Underperform rating but nudged its target up to $48 — almost exactly where the stock is now trading, an unusual positioning for a bear. Evercore ISI trimmed its Outperform target marginally to $59, signalling continued conviction on the upside. Cantor Fitzgerald raised its Neutral target sharply, from $43 to $52, suggesting the selloff has reopened valuation support. The consensus mean target at $51.78 implies modest recovery potential from current levels, though Morgan Stanley's June downgrade to Underweight — with a $53 target that now sits well above the price — hangs over the setup. The EV/EBITDA multiple at 16.1x has drifted higher over the past 30 days despite the price fall, reflecting the earnings compression embedded in forward estimates. EPS momentum scores rank in the 0th-to-3rd percentile, indicating persistent negative revisions.
The insider picture has shifted since the pre-earnings note. Joel Marcus's spring buying cluster — over 21,000 shares near $41-47 between May 4-6 — looked prescient when the stock recovered to $53. Now, with ARE back at $48.87, those positions remain modestly in the money but the thesis behind them faces a harder test. CEO Peter Moglia's most recent sale was on July 31 at $51.45, just days before the earnings drop. The net 90-day insider position remains net-buy at roughly 30,000 shares worth $1.35 million, but that reflects the historic Marcus accumulation rather than any fresh conviction signal. No new buys have appeared since the print. Across the peer group, the selloff is not an ARE-specific event — DOC fell 5.3% on the week, HR dropped 7.3%, and CHCT declined 6.9%, pointing to broad sector pressure rather than a company-specific collapse. MPT was the outlier, gaining 1.3% on the day.
The next scheduled earnings event is not until December 2. Between now and then, the watch items are whether Joel Marcus adds to his position at current levels — his May buying clustered around the $41-47 range, which is back in reach — and whether the call-heavy options positioning reflects genuine recovery conviction or a position that unwinds if the stock breaks below the spring lows.
See the live data behind this article on ORTEX.
Open ARE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
